Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
The triple-agonist injection also led nearly half of high-dose patients to lose 30% or more of their body weight, Lilly said.
- On Thursday, May 21, 2026, Eli Lilly announced that its investigational obesity treatment retatrutide cleared a Phase 3 clinical trial, with participants achieving up to 30.3% weight loss over 104 weeks.
- Dubbed the 'triple G' drug, retatrutide targets GLP-1, GIP, and glucagon hormone pathways, which Lilly said appears more potent than existing treatments at regulating appetite and metabolism.
- Yale School of Medicine Professor Ania Jastreboff, the study's lead investigator, called the results 'incredible,' noting participants on the highest dose lost an average of 70.3 lbs over 80 weeks.
- Results are on par with bariatric surgery, according to Lilly, though around 42% of patients on the highest dose experienced nausea, a common gastrointestinal side effect.
- Lilly plans to file for regulatory approval as early as this year, positioning retatrutide as a potential tool for patients who do not respond to current GLP-1 therapies.
73 Articles
73 Articles
Eli Lilly Says Next-Gen Weight Loss Drug Shows Results on Par with Bariatric Surgery
Pharma companies are one-upping each other’s GLP-1s. Eli Lilly said Thursday that its next-gen drug, retatrutide, cleared a late-stage trial, helping patients lose an average 29% of their weight over 80 weeks. Retatrutide is nicknamed the “triple G” drug because it targets GLP-1, GIP and glucagon while other drugs target one or two of the appetite-regulating hormones. About 45% of patients who received the highest dose of the weekly injection l…
Will an obesity treatment with even more powerful effects than bariatric surgery be released? Stock price rises 2.24% due to effects similar to bariatric surgery. In late-stage clinical trials targeting morbidly obese patients, the next-generation obesity treatment currently under development by the U.S. pharmaceutical company Eli Lilly showed levels similar to those of bariatric metabolic surgery.
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
